On July 17, Jiangsu Hengrui Pharmaceuticals (01276) spent 15.0888 million yuan to repurchase 280,000 A shares.
Hengrui Pharmaceutical (01276) announced that on July 17, 2026, the company spent 15.0888 million yuan to repurchase 280,000 A-shares.
Jiangsu Hengrui Pharmaceuticals (01276) announced on July 17, 2026, that the company will spend 15.0888 million yuan to repurchase 280,000 A shares.
Related Articles
On July 17th, LUYUAN GP HLDG (02451) spent 13.54 million Hong Kong dollars to repurchase 970,000 shares.
Tasly Pharmaceutical Group (600535.SH): Clinical trial approved for extending the time window for the indication of recombinant human urine plasminogen activator for acute ischemic stroke.
On July 17th, TIANGE (01980) repurchased 383,000 shares for a total amount of HK$226,000.
On July 17th, LUYUAN GP HLDG (02451) spent 13.54 million Hong Kong dollars to repurchase 970,000 shares.
Tasly Pharmaceutical Group (600535.SH): Clinical trial approved for extending the time window for the indication of recombinant human urine plasminogen activator for acute ischemic stroke.
On July 17th, TIANGE (01980) repurchased 383,000 shares for a total amount of HK$226,000.
RECOMMEND
